Tag Archives: FRI

Conference: Inhaled Drug Delivery – from 13 till 14 November in London

Conference: Inhaled Drug Delivery – from 13 till 14 November in London

Management Forum is currently having its 2-day annual conference inhaled drug development. Industry leaders are coming together on November 13 and 14 in London to discuss the current challenges, advancements and possibilities of current inhalation devices and technologies. A lot of attention is also going to the role of patients’ contribution to therapy in adequate… Continue Reading

FLUIDDA’s IPF Catalyst Challenge Entry

FLUIDDA is excited to join the IPF Catalyst Challenge! Functional Respiratory Imaging (FRI) is a very promising tool for early diagnosis, disease staging and progression and as a sensitive biomarker in drug development trials. As part of the challenge we would like to build a framework to enhance patient care through FRI because we believe… Continue Reading

Introduction to Functional Respiratory Imaging (FRI) for Investors and Market Analysts

For those who cannot attend our event coming Thursday at Flanders House in New York, you are welcome to register for the Webcast via following link: https://attendee.gotowebinar.com/register/8186175617140384514       FLUIDDA is delighted to invite you to a dedicated session discussing her proprietary Functional Respiratory Imaging (FRI) technology and its application in drug and device… Continue Reading

ERS Congress 2017 presentation slides downloads

ERS Congress 2017 presentation slides downloads

As the European Respiratory Society Conference has finished, we would like to share the presentation slides and posters FLUIDDA has presented. Please download. If you have any questions, please send us an email or ask a question on Twitter.   Sunday, September 10 Poster Discussions Thematic Posters   Monday, September 11 Oral Presentations Thematic Posters… Continue Reading

FLUIDDA’s FRI Technology was used in a Positive Phase II Trial with iNOpulse® for Treatment of Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD)

“Functional Respiratory Imaging (FRI) provided valuable insights throughout the development process of iNO in COPD patients with PH. The therapy was effective in the initial studies and has great potential to improve the lives of these severely affected patients” Dr. J. De Backer, CEO FLUIDDA   Changes in Blood Vessel Volume determined using Functional Respiratory… Continue Reading

FLUIDDA’s FRI technology will shine throughout ERS 2017

As the European Respiratory Society Conference is approaching rapidly, FLUIDDA is proud to announce that a total of 9 abstracts will be presented, highlighting the power of Functional Respiratory Imaging (FRI). FRI capabilities will be presented over a range of applications including: drug delivery optimization bronchodilation and non-invasive ventilation in COPD bronchoconstriction in asthma disease… Continue Reading

Study demonstrates validity and utility of FRI-based V/Q

Exciting new results will be presented at the upcoming European Respiratory Society Conference in Milan from 9-13 September! The primary function of the respiratory system is the transfer oxygen from the environment into the blood stream of a individual. Consequently in a healthy subject the regional ventilation in the lungs is well matched to the… Continue Reading

Study confirmed enhanced sensitivity of Functional Respiratory Imaging (FRI) compared to conventional lung function measures in IPF trial

” We were very impressed by the additional insights FRI brought to this clinical trial. The FRI data gave us confidence in the potential of this drug, supporting the signal observed in the lung function measurements. This type of information is very valuable when designing the next clinical trials for this compound.” Dr Piet Wigerinck, Chief… Continue Reading

FLUIDDA steps up FDA biomarker approval initiatives

In line with FDA commissioner’s, Dr Gottlieb, latest blog, FLUIDDA launched a comprehensive FDA Biomarker Approval initiative focusing on Idiopathic Pulmonary Fibrosis (#IPF), Chronic Obstructive Pulmonary Disease (#COPD), Bio-equivalence (#BE) and Lung Transplantation. As part of FDA’s critical path initiative FLUIDDA plans to submit several files demonstrating the added value of its Functional Respiratory Imaging (FRI)… Continue Reading

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

All content © FLUIDDA 2017